Position in ACLX
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$771,682,600
+$333,486,245 QoQ
Shares Held
6,720,803
0.0% QoQ
Ownership
11.5%
of shares outstanding
% of Portfolio
36.44%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ACLX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026GILEAD SCIENCES, INC. holds $2,117,784,503 across 6 Biotechnology names. ACLX ranks #1 (36.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ACLX |
Arcellx, Inc.
This page
|
6,720,803 | $771,682,600 | |
| 2 | RCUS |
Arcus Biosciences, Inc.
|
31,424,760 | $678,774,816 | |
| 3 | LKFT |
Lakefront Biotherapeutics NV
|
16,707,477 | $501,224,310 | |
| 4 | ASMB |
Assembly Biosciences, Inc.
|
4,505,391 | $125,024,600 | |
| 5 | KYTX |
Kyverna Therapeutics, Inc.
|
4,126,119 | $35,608,406 | |
| 6 | XLO |
Xilio Therapeutics, Inc.
|
650,389 | $5,469,771 |
All Filings in ACLX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-04-28 | $11,507 | 100 | Shares | Sole | 2026-04-28 | |
| 2026-03-31 | $771,682,600 | 6,720,803 | Shares | Sole | 2026-05-08 | |
| 2026-02-23 | $764,491,341 | 6,720,803 | Shares | Sole | 2026-02-23 | |
| 2025-12-31 | $438,196,355 | 6,720,803 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $551,777,926 | 6,720,803 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $442,564,877 | 6,720,803 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $440,884,676 | 6,720,803 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $515,418,382 | 6,720,803 | Shares | Sole | 2025-02-13 | |
| No filing history on record for this holder in this stock. | ||||||